The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
1
|
A | Alimentary tract and metabolism | |
2
|
A10 | Drugs used in diabetes | |
3
|
A10B | Blood glucose lowering drugs, excl. insulins | |
4
|
A10BH | Dipeptidyl peptidase 4 (DPP-4) inhibitors | |
5
|
A10BH04 |
The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.
| Code | Route | Amount | Notes |
|---|---|---|---|
| ORAL | Oral | 25 mg |
| Active Ingredient |
|---|
|
Alogliptin is a potent and highly selective inhibitor of DPP-4, >10,000-fold more selective for DPP-4 than other related enzymes including DPP-8 and DPP-9. Alogliptin improves glycaemic control via a glucose-dependent mechanism, whereby insulin release is enhanced and glucagon levels are suppressed when glucose levels are high. |
| Document | Type | Information Source | |
|---|---|---|---|
| NESINA Film-coated tablet | MPI, US: SPL/PLR | FDA, National Drug Code (US) | |
| VIPIDIA Film-coated tablet | MPI, EU: SmPC | European Medicines Agency (EU) |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.